News
While the primary target for these medication is weight loss, it’s not the only metric by which the drugs should be evaluated ...
Tirzepatide slashed weight by 20%, leading researchers to call this a new “golden age” for weight-loss therapies.
Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...
According to a study funded by Eli Lilly, the trial revealed that participants taking tirzepatide, the drug sold as ...
The best metric is not weight, but a particularly toxic kind of fat.
A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...
A U.S. federal judge has sided with a U.S. regulator's decision last year to take Eli Lilly’s blockbuster weight loss and ...
Some of the bankrupt company’s closest rivals, newer telehealth firms, face a new challenge of their own as federal ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback